XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders
6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

12. Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the three and six months ended June 30, 2023 and 2022, respectively (in thousands, except share and per share amounts):

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Net loss attributable to Adaptive Biotechnologies Corporation

 

$

(47,810

)

 

$

(52,046

)

 

$

(105,509

)

 

$

(114,782

)

Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

 

144,397,693

 

 

 

142,363,589

 

 

 

143,956,867

 

 

 

142,032,261

 

Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

$

(0.33

)

 

$

(0.37

)

 

$

(0.73

)

 

$

(0.81

)

Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three and six months ended June 30, 2023 and 2022, respectively, as they had an anti-dilutive effect:

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Stock options outstanding

 

 

14,556,602

 

 

 

14,693,276

 

 

 

14,180,632

 

 

 

13,978,339

 

Nonvested restricted stock units outstanding

 

 

11,007,405

 

 

 

5,364,447

 

 

 

8,956,361

 

 

 

3,983,640

 

Maximum nonvested market-based restricted stock units outstanding eligible to be earned

 

 

1,912,674

 

 

 

494,234

 

 

 

1,411,126

 

 

 

324,938

 

Total

 

 

27,476,681

 

 

 

20,551,957

 

 

 

24,548,119

 

 

 

18,286,917